We are a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through discovery and development of novel live biotherapeutic product, or LBP, candidates. We led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A., or SPN, and with certain of its affiliates, collectively, Nestlé Health Science, in September 2024.
Immune checkpoint inhibitor-related enterocolitis (irEC)(Stage not disclosed)
Status note Most advanced LBP candidate. Phase 1b in allo-HCT complete; final Phase 2 protocol submitted to FDA Jan 2026; company paused additional investment pending funding for the Phase 2 study. IST in moderate-to-severe irEC ongoing.
SER-603
Stage not disclosed · ActiveModality: live biotherapeutic (oral bacterial consortium)
Indications
Inflammatory bowel disease (ulcerative colitis, Crohn's disease)(Stage not disclosed)
Status note Novel live biotherapeutic product (LBP) candidate; company exploring collaborations for I&I programs.
SER-428
Stage not disclosed · ActiveModality: live biotherapeutic (oral liquid formulation)
Partnerships CARB-X: grant of up to $3,583 (second CARB-X award) supporting development of oral liquid formulation based on SER-155 strains.
Indications
AMR infections in medically vulnerable patients (e.g., intubated ICU)(Stage not disclosed)
Status note Oral liquid formulation of SER-155 strains for patients who cannot take capsules. No trial stage stated.
SER-147
Stage not disclosed · ActiveModality: live biotherapeutic (oral bacterial consortium)
Status note Named among LBP candidates; no indication or stage stated in excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.